Josiah Zayner cursed under his breath as blood pooled under the thin skin of his subject’s leg. He checked for vital signs: no breathing.
“I think I might have got the vein on that one accidentally,” he said.
Zayner, who had just administered an experimental injection, has a doctorate in biochemistry and biophysics from the University of Chicago, but to his patient such credentials were meaningless.
The leg in question belonged to a Hyla cinerea, a small green tree frog not more than two inches long. The idea was to inject a genetic cocktail to make the frog’s muscles grow larger.
A few hours later, the frog was back to its usually hoppy self, but it was touch-and-go for a while.
A year earlier, that gushing blood could have been Zayner’s own. He has garnered attention and headlines for administering experiments in a kind of performance-art-meets-biohacking theatric for a live audience and those watching on YouTube.
He once invited a reporter to witness a self-administered fecal implant to treat an irritable stomach; the procedure entailed swallowing a pill filled with a friend’s poop.
He attempted to genetically modify his skin cells to turn a patch a darker color. As he did to the frog, he has also injected himself with a DNA mix in a bid to bulk up his muscles. Should one feel inspired to recreate some of Zayner’s antics at home, he will sell you the tools to do so on his company Web site, The Odin.
Is this Silicon Valley’s answer to vaudeville? Or is Zayner at the forefront of a movement in which biotech is trickling down to garage entrepreneurs, in the same way that democratized computer and coding technology let curious tinkerers build Silicon Valley?
For now, Zayner has turned his attention to critters, after the US Food and Drug Administration issued a warning on the sale of gene-therapy products for DIY human use.
For US$499, anyone can order a kit containing six frogs, cages, food and all the materials necessary to replicate Zayner’s frog muscle therapy at home.
Zayner believes the experiment is legal: The US Animal Welfare Act exempts “cold-blooded” animals, including frogs, which the FDA regards as a “minor” species anyway.
Maybe not minor enough, though, after their DNA has been altered.
“The FDA does not regulate the kits you mention. However, the agency does regulate animals that contain intentionally altered genomic DNA,” an FDA spokesperson said.
The kits are the fruit of six months of experiments at Zayner’s West Oakland, California, laboratory, which houses dozens upon dozens of tree frogs — Zayner is not sure exactly how many.
The lab is a sophisticated, albeit less-than-sterile, space with an office fridge stocked with Red Bull and coconut water. His three full-time employees tap away on laptops filling orders, answering customer inquiries and helping design instruction materials. A big-screen TV livestreams a computer game competition. His younger brother lives upstairs.
Despite his body piercings and disdain for the slow pace of institutional science, Zayner has garnered a surprising amount of respect from the establishment. He is regularly asked to speak at conferences.
Last year, the famous Harvard University geneticist George Church signed on as an adviser to Zayner’s company. Church believes DIY bio is part of a long evolution of human activity that has culminated with rapid advancements in scientific fields such as genetics.
“DIY bio is a modern extension of ancient practices like breeding plants, animals [and] microbes,” Church said.
Zayner said that he wants to democratize science, helping people understand today’s technologies and make the most of what modern medicine has to offer.
He can veer toward grandiosity, having once prophesied a world where people would cure whatever ails them through their own genetic experimentation, or toy around with DNA recreationally.
“I don’t want to say I want to, like, take down the FDA, but we need to figure out a new model that works,” Zayner said, right before injecting the frogs with their first round of follistatin.
“There are a tonne of people dying and suffering that don’t have access to the drugs they need. Something is going to have to break eventually, right? I don’t know when and I don’t know what’s going to cause it, but maybe we can help push things forward,” he said.
After Zayner’s first public injection, a young, HIV-positive software engineer gave himself a vaccine meant to suppress HIV while streaming the endeavor on Facebook Live.
In February, Aaron Traywick, chief executive officer of a biotech start-up developing its own treatments outside the purview of regulators, announced onstage at a body-hacking conference that he had herpes, then took off his pants and injected his thigh with a “gene therapy” he claimed could both prevent and cure the virus.
Traywick’s death a few months later was unrelated to that or any DIY procedure; he drowned in a sensory-deprivation tank with ketamine in his system.
“[The] FDA is aware that gene therapy products intended for self-administration and do-it-yourself kits to produce gene therapies for self-administration are being made available to the public. The sale of these products is against the law. FDA is concerned about the safety risks involved,” the agency said in the warning.
Thus the pivot to amphibians.
Zayner says the evidence suggests they should work well for the tests. In one experiment he conducted, 12 frogs were given a different DNA mixture containing IGF-1, a human growth factor he hopes would make the frogs grow bigger than usual.
After several injections and a few weeks, their weight on average increased by about 23 percent. Six untreated frogs gained hardly any weight at all. Tests revealed that the DNA was in the frog’s liver, a sign the animal’s body was reproducing it.
Could Zayner’s frog experiments ever translate into safe DIY gene therapies for humans? Medical experts are not yet convinced.
“The idea that a homebrew guy could inject a frog and deduce whether the same therapy would work in a person” is a stretch, Stanford bioethicist Hank Greely said. “If this is a step toward successful DIY gene therapy, it is a very small step on a very long path.”
CHIP RACE: Three years of overbroad export controls drove foreign competitors to pursue their own AI chips, and ‘cost US taxpayers billions of dollars,’ Nvidia said China has figured out the US strategy for allowing it to buy Nvidia Corp’s H200s and is rejecting the artificial intelligence (AI) chip in favor of domestically developed semiconductors, White House AI adviser David Sacks said, citing news reports. US President Donald Trump on Monday said that he would allow shipments of Nvidia’s H200 chips to China, part of an administration effort backed by Sacks to challenge Chinese tech champions such as Huawei Technologies Co (華為) by bringing US competition to their home market. On Friday, Sacks signaled that he was uncertain about whether that approach would work. “They’re rejecting our chips,” Sacks
NATIONAL SECURITY: Intel’s testing of ACM tools despite US government control ‘highlights egregious gaps in US technology protection policies,’ a former official said Chipmaker Intel Corp has tested chipmaking tools this year from a toolmaker with deep roots in China and two overseas units that were targeted by US sanctions, according to two sources with direct knowledge of the matter. Intel, which fended off calls for its CEO’s resignation from US President Donald Trump in August over his alleged ties to China, got the tools from ACM Research Inc, a Fremont, California-based producer of chipmaking equipment. Two of ACM’s units, based in Shanghai and South Korea, were among a number of firms barred last year from receiving US technology over claims they have
It is challenging to build infrastructure in much of Europe. Constrained budgets and polarized politics tend to undermine long-term projects, forcing officials to react to emergencies rather than plan for the future. Not in Austria. Today, the country is to officially open its Koralmbahn tunnel, the 5.9 billion euro (US$6.9 billion) centerpiece of a groundbreaking new railway that will eventually run from Poland’s Baltic coast to the Adriatic Sea, transforming travel within Austria and positioning the Alpine nation at the forefront of logistics in Europe. “It is Austria’s biggest socio-economic experiment in over a century,” said Eric Kirschner, an economist at Graz-based Joanneum
OPTION: Uber said it could provide higher pay for batch trips, if incentives for batching is not removed entirely, as the latter would force it to pass on the costs to consumers Uber Technologies Inc yesterday warned that proposed restrictions on batching orders and minimum wages could prompt a NT$20 delivery fee increase in Taiwan, as lower efficiency would drive up costs. Uber CEO Dara Khosrowshahi made the remarks yesterday during his visit to Taiwan. He is on a multileg trip to the region, which includes stops in South Korea and Japan. His visit coincided the release last month of the Ministry of Labor’s draft bill on the delivery sector, which aims to safeguard delivery workers’ rights and improve their welfare. The ministry set the minimum pay for local food delivery drivers at